A Comparison of Rate Control and Rhythm Control in Patients with Recurrent Persistent Atrial Fibrillation (RACE)
Source: View publication →
The RACE trial demonstrated that a rate-control strategy is non-inferior to a rhythm-control strategy for preventing cardiovascular morbidity and mortality in patients with recurrent persistent atrial fibrillation.
Key Findings
Study Design
Study Limitations
Clinical Significance
The RACE trial provided essential evidence that rhythm control, which was historically favored, offered no morbidity or mortality advantage over a rate-control strategy for persistent atrial fibrillation, thereby establishing rate control as a valid, first-line management approach.
Historical Context
Prior to this trial, rhythm control was widely pursued with the assumption that maintaining sinus rhythm would improve patient outcomes despite the known risks of antiarrhythmic medications; RACE, along with the contemporary AFFIRM trial, fundamentally shifted clinical practice toward prioritizing symptom management via rate control.
Guided Discussion
High-yield insights from every perspective
In the RACE trial, why is achieving 'rate control' considered a physiological priority even if the patient remains in atrial fibrillation (AF), and what are the specific risks of leaving a high ventricular rate untreated?
Key Response
High ventricular rates reduce diastolic filling time, leading to decreased cardiac output and potential heart failure (tachycardia-induced cardiomyopathy). The RACE trial emphasizes that controlling this rate is as effective for mortality and morbidity as attempting to restore sinus rhythm, provided the heart is protected from the deleterious effects of chronic tachycardia.
The RACE trial found that many thromboembolic events in the rhythm-control group occurred after anticoagulation was discontinued. Based on this finding and current guidelines, what determines the need for long-term anticoagulation in an AF patient who has been successfully cardioverted to sinus rhythm?
Key Response
The RACE trial highlighted that perceived sinus rhythm is not a guarantee against stroke, often due to subclinical AF recurrence. Therefore, current guidelines (AHA/ACC/HRS) dictate that anticoagulation should be based on the patient's stroke risk profile (CHA2DS2-VASc score), regardless of the perceived success of rhythm control or the clinical AF pattern.
The rhythm control strategy in the RACE trial primarily utilized serial electrical cardioversions and class I/III antiarrhythmic drugs. How do the trial's findings regarding the difficulty of maintaining sinus rhythm (only 39% at the end of the study) reflect the 'AF begets AF' hypothesis of atrial remodeling?
Key Response
RACE included patients with persistent AF, who often have significant structural and electrical remodeling (atrial fibrosis and ion channel changes). This substrate makes maintaining sinus rhythm via drugs difficult. This highlights the concept that once persistent AF is established, the substrate is often too advanced for traditional pharmacologic rhythm control to be consistently effective compared to simple rate control.
The RACE trial is often cited alongside AFFIRM to justify a 'rate-control first' approach. However, if you were to apply the RACE findings to a modern patient, how would the 'toxicities' of early-2000s rhythm control (e.g., side effects of amiodarone/sotalol) contrast with modern catheter ablation outcomes seen in trials like CABANA or EAST-AFNET 4?
Key Response
RACE's rhythm control arm was hampered by the proarrhythmic and organ-toxic effects of older antiarrhythmic drugs, which likely offset any benefit of sinus rhythm. Modern practice shifting toward catheter ablation offers a more 'durable' and less toxic rhythm control, which newer evidence suggests may improve outcomes if initiated early, unlike the late-stage rhythm control attempted in RACE.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The RACE trial was designed as a non-inferiority study with a composite primary endpoint. Given its relatively small sample size (n=522) compared to the AFFIRM trial (n=4060), evaluate the risk of a Type II error and the implications of the chosen non-inferiority margin on the study's conclusions.
Key Response
With only 522 patients, RACE was potentially underpowered to detect modest but clinically significant differences between groups. A large non-inferiority margin or a low event rate can lead to an 'absence of evidence' being misinterpreted as 'evidence of absence' of harm, requiring meta-analyses (which later confirmed these findings) to provide more robust statistical confidence.
A notable percentage of patients in the RACE rhythm-control group crossed over to the rate-control group due to treatment failure. As a reviewer, why would you insist on seeing both an Intention-to-Treat (ITT) and a Per-Protocol (PP) analysis for this non-inferiority trial?
Key Response
In superiority trials, ITT is conservative as it dilutes the effect of the intervention. However, in non-inferiority trials, ITT can be 'anti-conservative' because crossovers and non-compliance make the groups look more similar, artificially favoring a claim of non-inferiority. Comparing ITT and PP results is critical to ensure the non-inferiority conclusion is not merely an artifact of treatment crossover.
How did the RACE trial findings contribute to the shift in the Strength of Recommendation for rate control in persistent AF, and how do these recommendations reconcile the trial's results with the newer EAST-AFNET 4 data which favors early rhythm control?
Key Response
RACE and AFFIRM provided the Level A evidence that rate control is a primary, acceptable strategy (Class I recommendation) for many patients. However, current guidelines now emphasize 'Early' rhythm control for those with recent-onset AF, as RACE primarily looked at patients with recurrent, persistent AF where remodeling was already established. The guidelines now distinguish between the 'rate control' approach for established AF and 'early rhythm control' to prevent progression.
Clinical Landscape
Noteworthy Related Trials
PIAF Trial
Tested
Rhythm control strategy (amiodarone)
Population
Patients with persistent atrial fibrillation
Comparator
Rate control strategy (diltiazem)
Endpoint
Improvement in symptoms and exercise tolerance
AFFIRM Trial
Tested
Rhythm control strategy
Population
Patients with atrial fibrillation at risk for stroke or death
Comparator
Rate control strategy
Endpoint
All-cause mortality
STAF Trial
Tested
Rhythm control strategy
Population
Patients with persistent atrial fibrillation
Comparator
Rate control strategy
Endpoint
Composite of death, cardiopulmonary resuscitation, stroke, and systemic embolism
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis